Mirae Asset Global ETFs Holdings
MGX icon

Mirae Asset Global ETFs Holdings’s Metagenomi Therapeutics MGX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,895
Closed -$21.6K – 3279
2025
Q1 		$21.6K Buy
15,895
+702
+5% +$1.67K ﹤0.01% 2977
2024
Q4 		$54.8K Buy
15,193
+11,730
+339% +$28.3K ﹤0.01% 2885
2024
Q3 		$7.51K Buy
+3,463
New +$12K ﹤0.01% 3045

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's MGX Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 15,895 shares — an estimated $21.6K sold.

Mirae Asset Global ETFs Holdings first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $54.8K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 15,895 Metagenomi Therapeutics shares in Q2 2025, an estimated $21.6K.
  • Mirae Asset Global ETFs Holdings first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Mirae Asset Global ETFs Holdings's Metagenomi Therapeutics position peaked at $54.8K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.